The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Evaluating the immunological effects.
 
Takashi Kojima
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; EA Pharma; Japan Esophageal Society; Japanese Society of Pharmaceutical Health Care and Sciences; Kyowa Kirin International; Liang Yi Hui Healthcare; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; CMIC; NPT Co.,Ltd.
Research Funding - Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hajime Shinohara
No Relationships to Disclose
 
Susumu Eguchi
No Relationships to Disclose
 
Naoki Izawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Keisho Chin
No Relationships to Disclose
 
Yoshihiro Tanaka
No Relationships to Disclose
 
Nozomu Machida
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masaaki Iwatsuki
No Relationships to Disclose
 
Katsunori Iijima
No Relationships to Disclose
 
Yosuke Horita
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); SHIONOGI (Inst); Yakult Honsha (Inst)
 
Hitoshi Ojima
No Relationships to Disclose
 
Seiichiro Mitani
Honoraria - MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer Pharma Japan. (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); Merus (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Hirai
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Ostuka HD
 
Hiroya Mizutani
Employment - Taiho Pharmaceutical
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Keiko Minashi
Research Funding - Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); PPD-SNBL (Inst); Taiho Pharmaceutical (Inst)